A report from the 2021 PDA/FDA Joint Regulatory Conference
The session ICH’s Initiatives to Advance Global Harmonization, Innovation, and Continual Improvement Throughout Lifecycle highlighted the revision of ICH Q9 and the implementation of ICH Q12.
Kevin O’Donnell, Market Compliance Manager from the Irish authority HPRA, gave an update on the ongoing revision of ICH Q9 on Quality Risk Management (QRM).
“QRM is a fundamental enabler for the Pharmaceutical Quality System,“ he opened his presentation. The initial discussions for a revision of ICH Q9 started in 2018. HPRA, EMA, an U.S. FDA colleague and an industry representative were involved and prepared the first proposal. The European Commision made a formal proposal to ICH for a revision in 2019. By November 2019, ICH made a decision to proceed with this suggested revision. The finalisation of the revised guideline is currently anticipated for May 2022.
The revision concerns 6 specific topics:
These topics will be addressed by adding new guidance that an by developing special training materials. Only for „Risk Review“ ICH Q9’s guidance is sufficient, but training materials will be developed, too.
“This is a very targeted revision of ICH Q9 – it is not a full rewrite. Most of the existing guidance will remain unchanged.“
Scientific approaches to QRM are also stressed in the Concept Paper for the revision. Another area of focus are new technologies and innovation in so far that the revision may support digitisation and emerging technologies, automation, and use of big data, PAT. Furthermore, quality defect issues are mentioned three times in the Concept Paper. This reflects that there are still unmitigated risks as a result of quality defects.
“Why do we need ICH Q12?“ Frank Montgomery from AstraZeneca asked in his enlightening talk about the implementation of ICH Q12 on pharmaceutical product lifecycle management. The need for ICH Q12 results from acceleration of clinical development. The CMC development goes beyond submission. The final supply chain or optimal devices are often introduced post-approval. Thus, the number of post-approval changes (PACs) has also been accelerated. The company’s portfolios are much more diverse than in former days. Another trigger for developing ICH Q12 is the diverse global regulatory environment for PACs. The total expected approval lead time for a world wide approval may even take up to 4 years!
AstraZeneca has already done a succesful ICH Q12 pilot submission in the U.S. for an oral product. They introduced established conditions (ECs) for the synthetic drug substance. The biopharmaceutical risk and impact to the drug product from changes to API were low. The benefits of introducing the tools ECs and PLCM were:
Exceptional circumstances call for exceptional action! Frank Montgomery reported that for AstraZeneca’s COVID vaccine the approval for a new drug substance site was approved in 7 calendar days!
A look at the worldwide progress on implementation of ICH Q12 revealed that up to now only the U.S. has published a national implementation document. All other regions are still in the middle of the process or are considering a pilot progam.
The European Commission (EC) emphasized that the already existing legal framework always takes precedence over technical and scientific guidelines. Some of ICH Q12’s tools and concepts are not foreseen in the EU legal framework (e.g. definition of ECs, PLCM). They will be considered when this framework will be reviewed. However, in the meantime, the EC is working on the implementation of ICH Q12 within the existing framework.
Here’s what you’ll learn:
Excerpt from the GMP Compliance Adviser